The World Anti-Doping Agency’s 2027 Prohibited List comes into effect on 1 January 2027, and its main change for readers of this site is about peptides. WADA now names peptides as examples in section S0 (non-approved substances) and warns that a peptide can be prohibited even if it is not named. The list also adds the “exercise mimetic” compounds SLU-PP-332 and SLU-PP-915 and the PPAR-delta agonist seladelpar to the metabolic modulators, and adds imlunestrant to the anti-estrogens. Everything that was banned stays banned: SARMs, MK-677, BPC-157, TB-500 and the PCT drugs remain prohibited at all times.
The changes that matter here
| Section | Change for 2027 | Related compounds on this site |
|---|---|---|
| S0 Non-approved substances | Wording now includes “peptides”; BPC-157 still named. WADA’s note: many unapproved peptides fall under S0, S2 or S4, and caution is needed even if a peptide is not named | BPC-157, GHK-Cu, epitalon |
| S4.4.1 Metabolic modulators | SLU-PP-332, SLU-PP-915 and related substances added; seladelpar added as a PPAR-delta agonist | SR9009, cardarine, MOTS-c |
| S4.2 Anti-estrogenic substances | Title expanded; imlunestrant added | tamoxifen, clomifene |
| S5 Diuretics and masking agents | Eplerenone and finerenone added | – |
What did not change
The 2027 List keeps the same named entries for the compounds we cover: SARMs such as ostarine (enobosarm), LGD-4033, RAD-140, S-23 and YK-11 under S1.2; MK-677, ipamorelin, CJC-1295 and tesamorelin under S2.2.4; IGF-1 analogs and TB-500 under S2.3; aromatase inhibitors such as anastrozole under S4.1; and SR9009, cardarine and MOTS-c under S4.4.1. All are prohibited in and out of competition. SARMs not named on the list, such as RAD-150, are covered by the class wording.
Other changes
Outside the compounds we cover, WADA clarified how metabolites of substances of abuse are handled, updated the cannabinoid section to reflect current knowledge of THC-like effects (cannabidiol itself is still not prohibited), added vaginal administration as a permitted route for glucocorticoids, and removed codeine, hydrocodone, dermorphin and, out of competition, fentanyl and tramadol from the monitoring program.
What it means for athletes
The peptide wording is the practical change. Many products are sold as “research peptides” with names that do not appear on the list. WADA’s position for 2027 is explicit: an unapproved peptide is likely prohibited anyway, and may be harmful. Contamination is a real risk too: anti-doping studies have detected SARMs in urine after doses of a few micrograms, the kind of amount a contaminated supplement can contain. See SARMs and WADA and SARMs drug test.
Frequently asked questions
When does the 2027 Prohibited List take effect?
1 January 2027Evidence: Law
WADA's 2027 Prohibited List comes into effect on 1 January 2027.
Are SARMs still banned in 2027?
YesEvidence: Law
SARMs remain prohibited at all times under S1.2 with the same named examples, and unnamed SARMs are covered by the class wording.
Are peptides like BPC-157 banned?
YesEvidence: Law
BPC-157 is named in S0, and for 2027 WADA adds "peptides" to the S0 wording and warns that unnamed peptides may still be prohibited.
What are SLU-PP-332 and SLU-PP-915?
Newly banned exercise mimeticsEvidence: Law
Experimental compounds sold as "exercise mimetics". WADA added them for 2027 as metabolic modulators (S4.4.1), the same section as SR9009 and cardarine.
Is GHK-Cu banned in 2027?
Not named, likely coveredEvidence: Law
It is not named, but S0 covers pharmacological substances without approval for human therapeutic use, and WADA warns that unnamed peptides may still be prohibited.
Sources
- World Anti-Doping Code International Standard: Prohibited List 2027 (valid 1 January 2027; archived copy of the official PDF)
- WADA 2027 Prohibited List: Summary of Major Modifications and Explanatory Notes
- World Anti-Doping Code International Standard: Prohibited List 2026
- Elimination profiles of microdosed ostarine mimicking contaminated products ingestion
- Human In Vivo Metabolism and Elimination Behavior of Micro-Dosed Selective Androgen Receptor Modulator RAD140 for Doping Control Purposes